EDITAS MEDICINE, INC. Deferred Income Tax Expense (Benefit)
EDITAS MEDICINE, INC. (EDIT) reported Deferred Income Tax Expense (Benefit) of $0 for the 3-month period ending 2016-03-31, per its 10-Q filed 2016-05-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2016-05-13
- EDITAS MEDICINE, INC. deferred income tax expense (benefit) for the quarter ending 2016-03-31 was $0.00.
- EDITAS MEDICINE, INC. deferred income tax expense (benefit) for the quarter ending 2015-03-31 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month |
|---|---|
| 2016-03-31 | $0.00 10-Q · filed 2016-05-13 |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |